| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c2e49aee49f55a20c16ab94f356a515 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate |
1997-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7b28dfa0bc48366c708379ed68c1b51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e25431c841e30b14133f54f7d98f06c |
| publicationDate |
1998-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0876147-A1 |
| titleOfInvention |
Use of galanthamine in the preparation of novel drugs |
| abstract |
Described is the use of galanthamine or one of its acid addition salts in the preparation of a drug for the treatment of trisomia 21 and related syndromes, glaucoma, myasthenia gravis and neuromuscular auto-immune illnesses and/or nerve-compression trauma. |
| priorityDate |
1996-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |